Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative FOLFIRINOX and Radiation for Borderline-Resectable Pancreatic Cancer
NCT01591733Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2012
- Primary completion
- Feb 2017
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of FOLFIRINOX, capecitabine in pancreatic cancer (PC), sponsored by Massachusetts General Hospital. Started Aug 2012; status: completed.
02
Drugs
FOLFIRINOXcapecitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01591733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01591733.